Moderna reiterates 10% revenue-growth target as Covid vaccine demand falls

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% revenue growth in 2026 following the launch of its next-generation Covid vaccine.

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.

Wall Street eyes Moderna earnings after FDA rebuff

Moderna will report its fourth-quarter 2025 earnings this morning in an investor call that’s taken on even more interest in light of this week’s row with the FDA.
Fierce Biotech

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from the $4.8 billion spent in 2023.
Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.
Fierce Pharma

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior administration and this administration.”

Moderna blames FDA for threatening US leadership in medicine

Moderna Inc. lashed out at the US Food and Drug Administration for making it harder for companies to create new medicines, escalating a dispute between the vaccine maker and the regulator.

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports